(HealthDay News) — A highly personalized therapy targeting multiple tumor antigens shows promise for metastatic breast cancer, according to a research letter published online June 4 in Nature Medicine.
Nikolaos Zacharakis, Ph.D., from the National Institutes of Health in Bethesda, Md., and colleagues present the case of a 49-year-old woman with chemorefractory hormone receptor-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes that were reactive against mutation versions of four proteins (SLC3A2, KIAA0368, CADPS2, and CTSB).
The researchers found that adoptive transfer of these mutant-protein-specific tumor-infiltrating lymphocytes with interleukin-2 and checkpoint blockade mediated a reduction in cancer, with the target tumor burden reduced by 51 percent at the first evaluable time points six weeks after cell transfer. At 22 months after cell transfer, all target and nontarget lesions had resolved radiologically.
“Metastatic breast cancer can be a heterogeneous disease, and this patient demonstrated that a personalized therapy tailored to target the unique somatic mutations presented by the autologous tumor of the affected individual can mediate complete durable cancer regression,” the authors write.